### ISHP.

Refocusing on Medication Safety: Best Practices for Injection Safety

Christina Michalek, BS, RPh, FASHP Medication Safety Specialist Michelle Mandrack, MSN, RN Director of Consulting Services

1

### CE Activity Information & Accreditation

 This CE activity is jointly provided by ProCE, LLC and the Institute for Safe Medication Practices (ISMP). ProCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Æ

 This CE activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers.

#### ISMP

2

### Disclosure

It is the policy of ISMP and ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation.

The speakers. listed helow have no relevant commercial and/or financial relationships to disclose Christina Michalek, BSc Pharm, RPh, FASHP Michelle Mandrack, MSN, RN

Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.

ISMP

Online Evaluation and	Statement of Completion
- <u>www.ProCE.com</u>	Pro CE
<ul> <li>Login with username and password</li> </ul>	Market All And
— Deadline: January 14, 2022	He d'Adamie Venetta Alleris All Activition D'Venta & Wellinson Home Starty Cestificate Popularia Additional Information
	Create that an Body Create that an Body Create that the Create the Create th
Attendance	e Code = ??????

4

#### Learning Objectives

Following completion of this activity, participants will be able to:

- 1. Identify how stressors, such as the COVID-19 pandemic, challenge medication safety efforts.
- Considering pandemic-related disruptions, list strategies to prevent medication errors, including the use of ready-to-administer preparations.
- 3. Describe three best practices for the use of IV push medications.
- 4. Explain how best practices for IV push medications can provide additional workflow benefits.

#### ISMP

5

### ISMP

Bringing Medication Safety Back into Focus

Christina Michalek, BS, RPh, FASHP Medication Safety Specialist Institute for Safe Medication Practices cmichalek@ismp.org

#### **Early Stages**

- Characterized by a lot of questions and a lot of practitioner-to-practitioner sharing
- Medication workflow related issues included limiting exposure and transmission
   Cleaning
  - Automated dispensing cabinet refilling changes
  - Medication delivery changes
  - Pause in elective care; move toward telehealth care
- Extremes in drug shortages
- Conserving resources
- Changing responsibilities

#### ISMP

7

#### Settling In

- Event questions and tags
  Is this event related to COVID-19?
- Elimination or modification of workflow steps
  Don and doff of personal protective equipment
- The "new normal"
  - What we stopped doing
  - What we gave up doing
  - What we continued to do
  - Where we still had risk

#### ISMP

8

#### **Present Challenges**

- Vaccination Positivity Rates Surges
- The burden of COVID-19 on healthcare providers
- New job responsibilities
- Supporting healthcare practitioners

ISMP

#### **Present Challenges**

- Supply chain challenges
- Drug shortages
- Pandemic job losses
  - Existing staffing shortages worsened by the pandemic
  - Recent poll indicates job changes (resigned 18%; 12-19% consider leaving)
- Prioritizing safety

### ISMP

10

### Pharmacy Specific Challenges

- "10 hospitals seeking pharmacy leaders" Becker's Hospital Review
- "More than 23,000 pharmacy jobs posted in October" JobRx
  - Health-systems (50%)
    Pharmacy technician (52%)
- Vaccine expansion; monoclonal antibodies
- Drug shortages; shifting priorities
- Staff shortages outside the pharmacy department

ISMP

11

Refocusing on safety: Risks with preparation of IV push medications

ISMP







14

#### **Compounding Outside the Pharmacy**

#### Most frequently prepared sterile injectables

- Intravenous push medications
  - Mostly medications transferred from vials to syringes (e.g., opioids, antiemetics, antibiotics, proton pump inhibitors)
- Intermittent infusions
- Mostly using vial and bag adapter systems
- Intramuscular injections
  - Mostly vaccines, antipsychotic and, antibiotics

ISMP





10

#### **Compounding Risks**

Risk for medication errors

- 31% aware of or personally experienced errors when preparing or admixing injectable medications
  - The practitioner preparing the medication or solution is often the one administering it
- Top errors
  - Wrong drug, dose, concentration, diluent or diluent volume (82%)
  - No label or labelling error (81%)

ISMP

17

### Compounding Risks

#### Sterility risks

 Microbial contamination of parenteral medications: clinical versus pharmacy environment

- Literature review

- PubMed and EMBASE search; publication dates: 2000-2018
- Significantly higher contamination rates for preparation of parenteral medication in the clinical environment
- Clinical area prepared products: Contamination rate = 1.09 20.7%
- Many potential contributing factors: environment, staff, training, frequency, aseptic technique

**ISMP** 18

### **Additional Risks**

#### Workflow time study: Wasting IV push opioids

- Primary objective: quantify the waste associated with administering select opioids IV push
- Waste included the amount of drug wasted and the time associated with the process
- Workflow time study design, a sub-set of continuous direct observation time motion studies was employed in inpatient care areas at two sites
- 669 distinct waste observations; combined loss of \$1605.39; workforce time waste \$489.51
  - Secondary measures: 86 observations included interruptions; average time removal to disposal 2 hours

ISMP

19

#### Pharmacy's Role

#### How can pharmacy minimize these risks?

- Work towards eliminating compounding outside the pharmacy
  - How?
  - Need to understand the what and why

#### ISMP







22

#### **Compounding Risks**

- 74% of all respondents were aware of at least one pharmacy compounding error in the past 12 months
  - This included those caught and corrected in the pharmacy as well as those discovered after dispensing
  - A higher percentage of pharmacists were aware of the errors (79%) compared to technicians (67%)

#### ISMP

23



#### **Additional Risks**

#### Potential for diversion in all settings

- Many of these medications are controlled substances
- 1 in 10 health professionals struggle with addiction or abusing drugs not prescribed
   10% 15% will inappropriately use substances over their career
- Healthcare workers pattern of drug abuse and dependency is unique to the general population
- Tends to follow drug availability
   Job related stressors
- See the positive effects drugs have on patients
- Comfort level with use; I'm in control
- Risk exposure: routinely supplying more than needed; allowing manipulation or products, especially when not supported, workflow required to close the loop

### **15MP** 25

Bringing safety into focus.

*What can we do <u>now</u> to support safety injection practices?* 

ISMP

26



### ISMP

#### **Bringing Medication Safety into Focus**

- Eliminate the need for compounding and potential risk of hospitalacquired infections by capitalizing on the purchase of commerciallymanufactured products
- Remove the need for compounding outside the pharmacy environment by dispensing intravenous push medications in ready-to-administer dosage forms
- Reduce the steps required for wasting controlled substances by providing patient-specific doses of intravenous push controlled substances in ready-to-administer dosage forms

ISMP

28





















35



#### **Unnecessary or Improper Dilution**

- Volume of diluent and method to determine the volume of diluent is variable
  - Most had personal formulas
    - 1 mL per minute of time needed to slowly administer drug
       Different if peripheral or central line
  - No respondents described a dilution process that would result
     in a specific concentration
  - 43% reported policies or guidelines on dilution

### 37

ISMP



38

### Misuse of Vials, Syringes, and Needles

- Survey on Carpuject<sup>™</sup> prefilled syringes (N=540)
  - Looking at issue of overfill and whether nurses were aware
  - Many nurses not concerned about overfill because they withdrew doses from the cartridges using a syringe
  - Using cartridges as single-/multipledose vials



39

ISMP



40



41

#### Wrong Rate Event

- $-\,$  Physician prescribed 20 mg labetalol IV bolus for ED patient with hypertensive crisis
- $-\,$  Nurse retrieved medication quickly but patient being moved to radiology
- Enroute, nurse administered the drug in seconds
- Patient immediately arrested



42

ISMP



43



44

#### **Absent Labeling Event**

- $-\mathsf{A}$  syringe containing vecuronium was prepared for a trauma patient
- -Medication not used, and syringe set down near saline flushes
- $-\mbox{Vecuronium}$  later used to flush the IV line of an alert 3-year-old girl
- -Child became flaccid and respiratory efforts ceased
- $-\ensuremath{\mathsf{Quickly}}$  intubated and ventilated, so permanent harm averted

ISMP









High Level	Failure-mode proposed strategies     Use commercially-available, or pharmacy-prepared patient-specific doses     Use automation and technology to assist human decision making
Mid-Level	Limit complexity and access     Provide decision support or remainders at the point of order entry,     verification, and administration     Consider the use of redundances e.g., independent checks     Provide ready to apply barcoded labels
Low Level	Create policies and expectations for practice     Educate providers about added risk     Validate compounding competencies



 Key Risk Reduction Strategies for Safety and Efficiency

 High Leverage

 Image: I



<text><section-header><section-header><image><image><list-item><list-item><list-item><list-item><list-item><list-item>

 Between the state of the state

52



53



Online Evaluation and S	tatement of Completion
<ul> <li><u>www.ProCE.com</u></li> <li>Login with username and</li> </ul>	
password — Deadline: January 14, 2022	
Attendance C	Image: Second